



Pathology and Laboratory Medicine Memorandum

To: Nova Scotia Health, St. Anne's Community Centre and IWK Physicians, Health
Service Managers, Nurse Educators

From: Transfusion Medicine, Department of Pathology and Laboratory Medicine

Date: March 4th, 2022

Message: Implementation of the NS Policy for C1 Esterase Utilization in Adults and Pediatrics
(Version 2)

Effective April 4th, 2022, Version 2 of the **NS Policy for C1 Esterase Utilization in Adults and Pediatrics** will be implemented.

Summary of key changes include:

- A change in the title from C1 Esterase Product Administration to NS Policy for C1 Esterase Utilization in Adults and Pediatrics.
- Changes to Appendix B: Indication and Dosing Table:
 - Berinert® dose and route of administration has been updated to state prophylaxis treatment is 20 International Units/kilogram twice per week.
 - Haegarda® has been added as a new product for long term prophylaxis and dosing is 60 International Units/kilogram subcutaneous, twice per week (greater than or equal to 12 years of age)

If you have any questions, please contact Jennifer LeFrense at 902-487-0504 or jennifer.lefrense@nshealth.ca